AbCellera Biologics Inc. (ABCL)
$11.34-$1.06 (-8.57%) Today
Latest ABCL Insider Trades
Michael R. Hayden - DirectorOpen-market purchase
Michael R. Hayden - DirectorMichael R. Hayden - DirectorAbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 147,200 | $1.55M |
| Grant or award | 5 | 639,517 | |
| Option exercise | 2 | 500,000 | |
| Bona-fide gift | 1 | 50,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
19 Form 4 filings on record, the earliest from Nov 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael R. Hayden - Director | Open-market purchase | Common Shares | 53,613 | $10.64 | $570K | |
| John S. Montalbano - Director | Open-market purchase | Common Shares | 10,000 | $11.03 | $110K | |
| Andrew Booth - Officer | Open-market purchase | Common Shares | 37,200 | $10.32 | $384K | |
| Michael R. Hayden - Director | Open-market purchase | Common Shares | 46,387 | $10.37 | $481K | |
| Michael R. Hayden - Director | Gift | Common Shares | 50,000 | $0.00 | - | |
 Lynn Seely - Director | Grant or award | Share option (right to buy) | 152,207 | $0.00 | - | |
| Victor Sandor - Director | Grant or award | Share option (right to buy) | 152,207 | $0.00 | - | |
| Michael R. Hayden - Director | Grant or award | Share option (right to buy) | 111,701 | $0.00 | - | |
| Stephen Quake - Director | Grant or award | Share option (right to buy) | 111,701 | $0.00 | - | |
| John S. Montalbano - Director | Grant or award | Share option (right to buy) | 111,701 | $0.00 | - | |
| Andrew Booth - Officer | Option exercise | Common Shares | 250,000 | $0.19 | $48K | |
| Andrew Booth - Officer | Option exercise | Share option (right to buy) | 250,000 | $0.00 | - | |
| John S. Montalbano - Director | Open-market purchase | Common Shares | 20,000 | $4.77 | $95K | |
| Thermopylae Holdings Ltd. - 10% Owner | Open-market purchase | Common Shares | 38,000 | $3.44 | $131K | |
| Thermopylae Holdings Ltd. - 10% Owner | Open-market purchase | Common Shares | 177,457 | $3.27 | $580K | |
| Andrew Booth - Officer | Open-market purchase | Common Shares | 42,600 | $3.42 | $146K | |
| John S. Montalbano - Director | Open-market purchase | Common Shares | 50,000 | $3.57 | $178K | |
| Michael R. Hayden - Director | Grant or award | Share option (right to buy) | 238,864 | $0.00 | - | |
| Thermopylae Holdings Ltd. - 10% Owner | Gift | Common Shares | 286,000 | $0.00 | - | |
| Carl L. G. Hansen - Officer | Option exercise | Common Shares | 56,125 | $2.70 | $152K | |
| Carl L. G. Hansen - Officer | Option exercise | Share option (right to buy) | 56,125 | $0.00 | - |
AbCellera Biologics Inc. (ABCL) had 11 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for ABCL runs to 19 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
4 insider purchases of ABCL were filed in the last 90 days, totaling $1.55M.
No insider sales of ABCL were filed in the last 90 days.
This page tracks ABCL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ABCL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
